Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST

ABSTRACT: CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST

PROVIDER: PRJNA1259987 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR33467735.fastq.gz	Fastqsanger.gz
	SRR33467736.fastq.gz	Fastqsanger.gz
	SRR33467737.fastq.gz	Fastqsanger.gz
	SRR33467738.fastq.gz	Fastqsanger.gz
	SRR33468245_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST.

Project description: Not available

| S-EPMC12366657 | biostudies-literature

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [331R]

Project description:Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that can develop from prostate cancer following aggressive hormonal therapy. Unfortunately, there are few treatment options available and new therapeutic targets and more effective treatments are urgently needed to improve management of the disease. There is now little doubt that the majority of NEPC is derived from prostatic adenocarcinoma cells via “NE transdifferentiation” that is driven at least in part by AR-axis interference and lineage plasticity. We have developed a first-in-field patient-derived xenograft model of a prostatic adenocarcinoma (LTL331) that undergoes a complete transdifferentiation to NEPC (LTL331R) upon host castration. Using this unique, high-fidelity, patient-derived prostate cancer xenograft models and powerful genomic and transcriptomic analyses, we have obtained evidence that therapy induced development of NEPC may result from epigenetic alterations which drives lineage plasticity of dormancy-capable cancer cells and functional evaluation of key regulators. These findings may lead to more suitable targets and better therapeutic strategies for prevention and treatment of NEPC.

2025-05-11 | GSE296569 | GEO

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [331R-2D]

2025-05-11 | GSE296567 | GEO

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [331R]

Project description:CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [331R]

| PRJNA1259989 | ENA

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [16D CRPC xenograft]

2025-05-11 | GSE296568 | GEO

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [331R-2D]

Project description:CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [331R-2D]

| PRJNA1259984 | ENA

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [16D CRPC xenograft]

Project description:CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [16D CRPC xenograft]

| PRJNA1259981 | ENA

CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-05-11 | GSE296570 | GEO

Lasp1 gene disruption is linked to enhanced cell migration and tumor formation

Project description:Chronic loss of Lasp1 alters the expression of other genes associated with cell motility/attachment, and/or other cellular functions. Results provide new information showing that loss of Lasp1 leads to up- and down-regulation of genes involved in cell motility/attachment/growth. Keywords: Genotype comparison Total RNA isolated from Lasp1-/- MEFs compared to Lasp1+/+ MEFs.

2010-06-23 | E-GEOD-14800 | biostudies-arrayexpress

Identify FOXA2-interacting proteins in NEPC cells

Project description:Following extensive treatment with androgen receptor (AR) pathway inhibitors, a significant number of metastatic prostate cancer develop treatment resistance, and approximately 20% of these castration-resistant prostate cancers (CRPC) transdifferentiate, at least partially, into neuroendocrine (NE) prostate cancer (NEPC).In human cancer, FOXA2 is highly expressed in most of NEPC and a small portion of CRPC patients, has been suggested as a marker of NEPC and elevated in other NE lineage cancers including SCLC. In addition, preclinical studies demonstrated that Foxa2 is required for NEPC tumor growth and metastasis in TRAMP mouse model and associated with NEPC transformation in Pten, Trp53, and Rb1 triple knockout mouse model. However, whether FOXA2 is an essential driver of NEPC, and the underlying mechanism in shaping epigenetic landscape of NEPC is largely unknown.

2025-06-12 | PXD061127 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data